Hoffmann-La Roche: Breast Neoplasms trials

The registry lists 229 Breast Neoplasms studies with Hoffmann-La Roche as lead sponsor. 17 are open to participants now and 123 have results posted.

Phase 1 38Phase 2 78Phase 3 63Phase 4 11No phase 52(a study in two phases counts in both)

Studies

Page 2 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast CancerCompletedNCT00976989Phase 2Results posted
• A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast CancerCompletedNCT00951665Phase 1/2Results posted
• A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast CancerCompletedNCT00950300Phase 3Results posted
• Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease ProgressionCompletedNCT00943670Phase 2Results posted
• A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast CancerCompletedNCT00934856Phase 1/2Results posted
• A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing RegimenCompletedNCT00932373Phase 1Results posted
• A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast CancerCompletedNCT00929240Phase 3Results posted
• A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast CancerCompletedNCT00885755Phase 2Results posted
• A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received TrastuzumabCompletedNCT00875979Phase 1/2Results posted
• A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast CancerCompletedNCT00846027Phase 2Results posted
• A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast CancerCompletedNCT00829166Phase 3Results posted
• A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast CancerCompletedNCT00811135Phase 2Results posted
• A Dose-Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive FemalesCompletedNCT00800436Phase 1Results posted
• A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast CancerTerminatedNCT00796107Phase 2Results posted
• An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)CompletedNCT00726661Results posted
• A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.CompletedNCT00717405Phase 2Results posted
• A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic DiseaseCompletedNCT00679341Phase 2Results posted
• A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast CancerCompletedNCT00679211Phase 2Results posted
• A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer.TerminatedNCT00576901Phase 2Results posted
• A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast CancerCompletedNCT00567190Phase 3Results posted
• A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast CancerCompletedNCT00559845Phase 2Results posted
• A Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer.CompletedNCT00559754Phase 2Results posted
• A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.CompletedNCT00545688Phase 2Results posted
• BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast CancerCompletedNCT00528567Phase 3Results posted
• A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast CancerCompletedNCT00509769Phase 2Results posted
• A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast CancerCompletedNCT00475670Phase 2Results posted
• A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.CompletedNCT00448591Phase 3Results posted
• THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.CompletedNCT00448279Phase 3Results posted
• A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.CompletedNCT00444587Phase 2Results posted
• A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)TerminatedNCT00434356Phase 2Results posted
• A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.CompletedNCT00391092Phase 3Results posted
• A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast CancerCompletedNCT00333775Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2)CompletedNCT00281697Phase 3Results posted
• A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)Status unknownNCT00262067Phase 3Results posted
• XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast CancerCompletedNCT00127933Phase 4Results posted
• A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast CancerCompletedNCT00121836Phase 4Results posted
• A Study of Xeloda (Capecitabine) in Women With High-Risk Breast CancerCompletedNCT00089479Phase 3Results posted
• A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast CancerCompletedNCT00077857Phase 2Results posted
• Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast CancerCompletedNCT00045032Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast CancerCompletedNCT00022672Phase 3Results posted
• A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast CancerTerminatedNCT07214662Phase 1
• A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)Active, not recruitingNCT06065748Phase 3
• A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast CancerCompletedNCT05945927
• A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast CancerCompletedNCT05852691Phase 2
• A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)Active, not recruitingNCT05306340Phase 3
• A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)Active, not recruitingNCT05296798Phase 3
• P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid TumorsActive, not recruitingNCT05239143Phase 1
• A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Active, not recruitingNCT04961996Phase 3
• A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative TherapyActive, not recruitingNCT04873362Phase 3
• A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)Active, not recruitingNCT04546009Phase 3
• An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 PandemicApproved for marketingNCT04395508
• A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin AmericaCompletedNCT04158258
• A Study to Assess the Feasibility of an E-Health System (ZEMY) Designed to Manage Symptoms in Participants With Breast Cancer Under Anti-Cancer TreatmentCompletedNCT03558490Phase 2
• A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast CancerActive, not recruitingNCT03332797Phase 1
• Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast CancerCompletedNCT03153163Phase 1
• An Observational Study Evaluating the Productivity and Health-Related Quality of Life of People With HER2 Positive Breast CancerCompletedNCT03099200
• Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast CancerCompletedNCT03084939Phase 3
• To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast CancerActive, not recruitingNCT03006172Phase 1
• Study of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Participants With Early/Metastatic Breast Cancer in Saudi ArabiaCompletedNCT02954471
• A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)CompletedNCT02913456
• To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast CancerCompletedNCT02846428Phase 2
• A Study to Determine Biopsy Rate in Participants With a First Relapse of Breast CancerCompletedNCT02761616
• A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)CompletedNCT02738970Phase 1
• A Study on the Epidemiology and Testing of Human Epidermal Growth Factor-Receptor 2 (HER2) in Breast Cancer in GermanyCompletedNCT02666261
• A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)CompletedNCT02627274Phase 1
• Effect of GDC-0810 on the Pharmacokinetics of Pravastatin in Healthy Female Subjects of Non-Childbearing PotentialCompletedNCT02621957Phase 1
• A Study To Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast CancerWithdrawnNCT02616224
• A Study to Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC)TerminatedNCT02611310
• Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast CancerCompletedNCT02605915Phase 1
• A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast CancerCompletedNCT02595762
• Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)Active, not recruitingNCT02568267Phase 2
• An Observational Study in Patients With Breast Cancer and Bone Metastases Receiving Ibandronate (Bondronat)CompletedNCT02553850
• A Survey of Breast Cancer Patients With Metastatic Bone Disease Receiving Oral IbandronateCompletedNCT02528747
• Safety of Xeloda in Solid TumoursCompletedNCT02479217
• A Study to Determine the Safety and Tolerability of Herceptin as an Adjuvant Therapy of Early Breast CancerCompletedNCT02443467
• Safety of Herceptin/Trastuzumab in Metastatic Breast CancerCompletedNCT02424682
• Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast CancerCompletedNCT02402712Phase 3
• Human Epidermal Growth Factor Receptor 2 (HER2) Positive Unresectable Locally Advanced or Metastatic Breast Cancer Disease Registry StudyCompletedNCT02393924
• A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast CancerCompletedNCT02316509Phase 1
• An Observational Study of Kadcyla Safety in Breast CancerCompletedNCT02305641
• An Observational Study of Herceptin SC Safety in Breast CancerCompletedNCT02305628
• An Observational Study of the Safety of Herceptin Given Subcutaneously in Patients With Early HER2-positive Breast CancerCompletedNCT02286362
• Observational Study of Pertuzumab Safety in Participants With Breast CancerCompletedNCT02266173
• A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual AdministrationCompletedNCT02194166Phase 3
• A Study of SC Administration of Trastuzumab (Herceptin) by SID at Home in HER2-Positive EBC ParticipantsCompletedNCT02040935Phase 3
• H.E.R.O.S. Study: An Observational Study of the Cardiac Safety of Herceptin (Trastuzumab) in Patients With HER2-Positive Breast CancerCompletedNCT01991340
• A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast CancerCompletedNCT01964391Phase 3
• A Study of Trastuzumab Subcutaneous in Participants With Human Epidermal Growth Factor Receptor-2 (HER2) Positive Early Breast CancerCompletedNCT01959386
• A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 ProteinCompletedNCT01918254Phase 1
• A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung CancerCompletedNCT01862081Phase 1
• A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 YearsCompletedNCT01810393Phase 3
• HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin TherapyCompletedNCT01777958
• A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast CancerCompletedNCT01740336Phase 2
• An Observational Study of Avastin (Bevacizumab) in Combination With Paclitaxel in First-Line Treatment in Patients With HER2-Negative Metastatic Breast CancerCompletedNCT01661153
• An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)CompletedNCT01615068
• An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)CompletedNCT01598597
• A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic FunctionCompletedNCT01513083Phase 1
• A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid TumoursCompletedNCT01493336Phase 1
• An Observational Study to Register the Incidence of Breast Cancer and Current Clinical Care Patterns in KenyaCompletedNCT01484483
• Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor TherapyCompletedNCT01437566Phase 2